Modelled DT Structure
Method: multi-sequence alignment based machine learning
Detail: Structure Info
| General Information of DT | |||||
|---|---|---|---|---|---|
| DT ID | DTD0126 | ||||
| Gene Name | SLC19A1 | ||||
| Protein Name | Folate transporter 1 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| TCDB ID | |||||
| 3D Structure |
Modelled DT Structure Method: multi-sequence alignment based machine learning Detail: Structure Info |
||||
| Synonyms | CHMD; FLOT1; FOLT; IFC-1; IFC1; Intestinal folate carrier 1; Placental folate transporter; REFC; RFC; RFC1; Reduced folate carrier protein; SLC19A1; Solute carrier family 19 member 1 | ||||
| DT Family | Reduced Folate Carrier (RFC) Family ; | ||||
| Tissue Specificity | Placenta, liver, and to a much smaller extent,in lung. | ||||
| Function | This transporter mediates the uptake of folate in human placental choriocarcinoma cells occurs by a novel mechanism called potocytosis which functionally couples three components, namely the folate receptor, the folate transporter, and a V-type H(+)-pump. | ||||
| Disease(s) | Malignant pleural mesothelioma [ICD-11: 2C26.0] | ||||
| Peripheral T-cell lymphoma [ICD-11: 2A90.C] | |||||
| Vitamin deficiency [ICD-11: 5B55-5B7Z] | |||||
| Endogenous Substrate(s) | Folate derivatives | ||||
| Variability Data of This Drug Transporter (DT) | |||||
|
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
|
(β) Post-translational Modification of This DT |
|||||
|
(γ) Transcriptional Regulation of This DT |
|||||
|
(δ) Epigenetic Regulation of This DT |
|||||
|
(ε) Exogenous Modulation of This DT |
|||||
|
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
|
(β) Inter-species Structural Differences |
|||||
|
General Variability Data of This DT (VARIDT 1.0) |
|||||
|
(α) Genetic Polymorphisms of This DT |
|||||
|
(β) Disease-specific Protein Abundances of This DT |
|||||
|
(γ) Species- and Tissue-specific DT Abundances |
|||||
| Molecular Transporting Profile of This DT | |||||
|
Full List of Drug(s) Transported by This DT |
|||||
|
Approved Drug |
Click to Show/Hide the Full List of Drug: 4 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
|
Folic acid
|
Approved | Drug Info | Vitamin deficiency | 5B55-5B7Z | [1] |
|
Methotrexate
|
Approved | Drug Info | Leukemia | 2A60-2B33 | [1] |
|
Pemetrexed
|
Approved | Drug Info | Malignant pleural mesothelioma | 2C26.0 | [1] |
|
Pralatrexate
|
Approved | Drug Info | Breast cancer | 2C60-2C6Z | [2] |
|
Drug-DT Affinity Assessed by Cell Line |
|||||
|
Approved Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
| Pemetrexed | Approved | Drug Info | Human liver cancer cells (HepG2)-FLOT1 | Km = 0.2 microM | [2] |
| References | |||||
| 1 | Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr. 2014;73:175-204. | ||||
| 2 | Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012 Aug;15(4):183-210. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.